ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4972ometendo-4972Research ArticleСтатьиArticlesАкласта (золедроновая кислота) в малых дозах эффективна при остеопении у женщин в постменопаузе: данные рандомизированного, плацебо-контролируемого исследованияLow-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trialVorotnikovaS Yu-20121509201293№3 (2012)3737Copyright © Vorotnikova S.Y., 20122012Vorotnikova S.Y.Vorotnikova S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4972

Реферат по статье: Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2012;97(1):286-92. doi: 10.1210/jc.2011-2081.

Discussionты for the article "Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial" (Grey A. et al., 2012).

ReferencesGrey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2012;97(1):286-92. doi: 10.1210/jc.2011-2081.Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2012;97(1):286-92. doi: 10.1210/jc.2011-2081.

The authors declare that there are no conflicts of interest present.